Table 2.
Univariate and Cox proportional hazards regression analyses of each factor’s using the training cohort.
| Variable | Number of patients | CSS (%) | Univariate | Multivariate | |||
|---|---|---|---|---|---|---|---|
| Log-rank test | P | Hazard Ratio | 95% CI | P | |||
| Age (years) | 4.007 | 0.045 | |||||
| <65 | 353 | 20.4 | 1 | ||||
| ⩾65 | 343 | 15.7 | 1.107 | 0.928–1.322 | 0.259 | ||
| Sex | 0.960 | 0.327 | |||||
| Male | 421 | 20.0 | |||||
| Female | 275 | 15.3 | |||||
| Race | 2.554 | 0.11 | |||||
| White | 450 | 16.0 | |||||
| Other | 246 | 22.0 | |||||
| Grade | 14.943 | 0 | |||||
| Well/moderately differentiated | 149 | 26.2 | 1 | ||||
| Poorly differentiated | 547 | 15.9 | 1.473 | 1.188–1.827 | 0 | ||
| T stage | 16.975 | 0 | |||||
| 1 + 2 | 47 | 48.9 | 1 | ||||
| 3 + 4 | 649 | 15.9 | 1.94 | 1.278–2.945 | 0.002 | ||
| N stage | 7.418 | 0.006 | |||||
| 0 + 1 | 342 | 21.3 | 1 | ||||
| 2 + 3 | 354 | 15.0 | 1.226 | 1.034–1.455 | 0.019 | ||
| Tumor site | 7.013 | 0.135 | |||||
| Proximal third | 129 | 21.7 | |||||
| Mid third | 170 | 17.6 | |||||
| Distal third | 259 | 17.8 | |||||
| Greater curvature | 48 | 12.5 | |||||
| Overlapping | 90 | 17.8 | |||||
| Metastatic sites | 15.498 | 0 | |||||
| Distant lymph node(s) only | 105 | 28.6 | 1 | ||||
| Organ | 538 | 16.2 | 1.603 | 1.252–2.054 | 0 | ||
| Overlapping | 53 | 17.0 | 1.47 | 1.010–2.141 | 0.044 | ||
| Chemotherapy | 17.606 | 0 | |||||
| With | 375 | 18.7 | 1 | ||||
| Without/unknown | 321 | 17.4 | 1.495 | 1.254–1.783 | 0 | ||
| Tumor size (cm) | 1.510 | 0.219 | |||||
| ⩽60 | 364 | 16.8 | |||||
| >60 | 332 | 19.6 | |||||
CSS, cancer-specific survival.